Aspirin-exacerbated respiratory disease common in chronic rhinosinusitis with nasal polyps
LOS ANGELES — Aspirin-exacerbated respiratory disease was found in 16% of patients with chronic rhinosinusitis with nasal polyps and was associated with more severe disease, according to recent study findings presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
“Aspirin-exacerbated respiratory disease (AERD) comprises the triad of chronic rhinosinusitis with nasal polyps (CRSwNP), asthma and intolerance to cyclooxygenase-1 enzyme inhibitors such as aspirin,” Whitney W. Stevens, MD, PhD, of Northwestern University Feinberg School of Medicine, told Healio.com/Allergy. “The prevalence of AERD remains unclear and few studies have compared the clinical characteristics of patients with AERD to those with CRSwNP or asthmatics without CRS.”
Stevens and colleagues searched electronic medical records from a tertiary care center to find patients diagnosed with only CRSwNP (n = 459), with both CRSwNP and asthma (n = 412) and with AERD alone (n = 173). Using the same medical records, the researchers established a comparison group (n = 300) with only asthma to evaluate lung function, sinus surgeries and oral corticosteroid use.
Sixteen percent of patients with only CRSwNP had AERD. Patients with AERD underwent twice as many sinus surgeries (P < .001) and were an average of 3 years younger than patients with CRSwNP alone (P < .05).
In addition, researchers found atopy in 83% of patients with AERD and 85% of patients with asthma , but only 66% of patients with CRSwNP (P < .05). FEV1 was lower in AERD patients vs. asthmatics (80% vs. 86%; P < .01).
Thirteen percent of patients with AERD had corticosteroid-dependent disease whereas only 4% of patients with both CRSwNP and asthma had the disease, as well as 1% of patients with only asthma (P < .01).
“This is one of the largest studies comparing surgical and non-surgical AERD patients with CRSwNP patients and asthmatics,” Stevens said. – by Will Offit
Stevens WW, et al. Abstract 210. Presented at: American Academy of Allergy, Asthma & Immunology Annual Meeting; March 4-7, 2016; Los Angeles.
Disclosure: Healio.com/Allergy could not confirm disclosures at the time of reporting.